Biotech Values

[iwfal]

EXEL XL184 poster - one thing they did do in the poster was elucidate the pain improvement. It didn't actually look that good to me:

60% had improvement at week 6 or week 12.

Note the 'or'. And note the apparent lack of a threshold. From memory I believe that with Tax 324 (327? ?) the SOC group got 20 something percent with a threshold and a scheduled measurement point. Docetaxel got somewhat better results although I don't remember the amount. Given that comparative data 60% doesn't look a lot better than SOC from Tax 327.

PS If there was a meaningful threshold then the 60% might mean something - but given the 'or' it still isn't something I'd count on.